Related Experiment Video
Updated: Mar 3, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Proteasome inhibitors in glioblastoma
Wen-Juan Huang1, Wei-Wei Chen2, Xia Zhang3
1Department of Neurology, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China.
Abstract:
Glioblastomas (GBM) are the tumors originating from the star shaped supportive cells in brain known as astrocytes. These tumors are highly cancerous as they have the ability to proliferate very quickly. New therapeutic strategies are being developed worldwide to fight against deadly GBM, which has median survival time of just 14 months. Proteasome inhibition is an upcoming strategy for GBM. Proteasome inhibition has shown promising results in cancers such as myeloma. However, in the recent past this form of therapy has also shown positive results in brain tumors in the form of elevated apoptosis. We searched the electronic database PubMed for pre-clinical as well as clinical controlled trials reporting importance of proteasome inhibitors during GBM. It was observed clearly that this approach is evolving and has been observed to be promising therapeutic avenue against GBM. Thus, the present review aims to enlighten the present views on use of proteasome inhibition strategy in the case of GBM.
Insights
Proteasome inhibition is a promising new therapy for glioblastoma (GBM), a fast-growing brain tumor. This strategy shows potential for increasing cancer cell death and improving GBM treatment outcomes.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Pharmacology
Background:
- Glioblastomas (GBM) are aggressive brain tumors originating from astrocytes.
- GBM has a poor prognosis with a median survival of only 14 months.
- Novel therapeutic strategies are urgently needed for GBM treatment.
Purpose of the Study:
- To review the current evidence on proteasome inhibition as a therapeutic strategy for GBM.
- To evaluate the potential of proteasome inhibitors in treating glioblastoma.
- To highlight the evolving role of proteasome inhibition in neuro-oncology.
Main Methods:
- Literature search of PubMed for pre-clinical and clinical controlled trials.
- Focus on studies investigating proteasome inhibitors in GBM.
- Review and synthesis of existing research findings.
Main Results:
- Proteasome inhibition has demonstrated promising results in various cancers, including myeloma.
- Emerging evidence suggests positive outcomes in brain tumors, including elevated apoptosis.
- The approach is evolving and shows potential as a therapeutic avenue for GBM.
Conclusions:
- Proteasome inhibition represents a promising and evolving therapeutic strategy for glioblastoma.
- This approach has shown efficacy in inducing apoptosis in brain tumors.
- Further research and clinical trials are warranted to fully establish its role in GBM treatment.
Related Concept Videos
02:18The Proteasome
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...